This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers | MicrobiomeTrials
← Back to trials NCT05616624
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers TERMINATED PHASE1, PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2023-04-05Est. Completion: 2026-07-22
Enrollment target: 31 participantsLocations Northwestern University, Chicago, Illinois, United States Washington University School of Medicine, St Louis, Missouri, United States Inova Schar Cancer Institute, Fairfax, Virginia, United States Other microbiome trials you might be interested in Advanced or Metastatic NSCLC
This study will assess safety, tolerability, and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination …
La Jolla, United States Est. completion May 4, 2026
Extensive-Stage Small Cell Lung Cancer Extrapulmonary Neuroendocrine Carcinoma Recurrent or Refractory Solid Tumors
Background:
Small cell lung cancer (SCLC) is the deadliest form of lung cancer. Extrapulmonary neuroendocrine cancer (E…
Bethesda, United States Est. completion Jan 30, 2030